Hims & Hers won't sell compounded version of Novo’s obesity pill
statnews.com • • business
Key Points:
- Hims & Hers announced it will stop selling a compounded, cheaper version of Novo Nordisk’s obesity pill on its telehealth platform following health officials' concerns about possible federal law violations.
- The compounded drug was launched at $49 per month, significantly undercutting Novo Nordisk’s official oral version priced between $149 and $299 per month.
- Novo Nordisk criticized the mass production of the compounded drug, noting that such copies are typically only allowed during drug shortages.
- The FDA pledged to take strong action against companies mass marketing unapproved compounded GLP-1 drugs like Hims.
- The Department of Health and Human Services has requested the Department of Justice to investigate Hims for potentially violating federal regulations.
